symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
ELVN,13.12,0,101343,539902432,0,3.365-24.8,0.55,"Enliven Therapeutics, Inc.",USD,0001672619,,,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.enliventherapeutics.com,"Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.",Mr. Samuel S. Kintz M.B.A.,Healthcare,US,37,720 647 8519,6200 Lookout Road,Boulder,CO,80301,,0,https://financialmodelingprep.com/image-stock/ELVN.png,2020-03-12,True,False,True,False,False
